Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;19(3):2021-2027.
doi: 10.3892/ol.2020.11255. Epub 2020 Jan 7.

Role of HSP27 in the multidrug sensitivity and resistance of colon cancer cells

Affiliations

Role of HSP27 in the multidrug sensitivity and resistance of colon cancer cells

Zhengyong Liu et al. Oncol Lett. 2020 Mar.

Abstract

Multidrug resistance in cancer cells is a primary factor affecting therapeutic efficacy. Heat shock 27 kD protein 1 (HSP27) is associated with cell apoptosis and resistance to chemotherapy. However, the mechanisms underlying HSP27-associated pathways in colon cancer cells remain unclear. Therefore, the present study used short hairpin (sh) RNA to inhibit HSP27 expression in colon cancer cells in order to investigate the effects in vitro and in vivo. Flow cytometry was used to investigate cell apoptosis and a xenograft model was employed to examine the tumorigenesis. Protein expression was measured by Western blotting. The results revealed that suppression of HSP27 expression significantly increased cell apoptosis, inhibited tumor growth and enhanced sensitivity to the anti-cancer agents 5-fluorouracil (5-FU) and vincristine (VCR). shHSP27 significantly decreased the expression of notch receptor 1 and the phosphorylation level of Akt and mTOR, and enhanced the effect of 5-FU and VCR. In conclusion, HSP27 suppression enhanced the sensitivity of colon cancer cells to 5-FU and VCR, and increased colon cancer cell apoptosis with and without chemotherapy. Therefore, the development of novel therapeutic agents that inhibit the expression of HSP27 may offer a new treatment option for colon cancer.

Keywords: colon cancer; heat shock 27 kD protein 1; multidrug sensitivity; notch receptor 1-Akt-mTOR pathway.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Effect of shHSP27 on HSP27 expression (A) in vitro and (B) in vivo. Results are expressed as the ratio of HSP27 and β-actin. *P<0.05 vs. the others. n=4 in each group. sh, short hairpin; HSP27, heat shock 27 kD protein 1; NC, negative control.
Figure 2.
Figure 2.
Annexin V-FITC/PI staining of SW480 cells with/without shHSP27 and chemotherapy. *P<0.05 vs. the other groups, #P<0.05 vs. control + 5-FU group, &P<0.05 vs. control + VCR group. n=5 in each group. sh, short hairpin; HSP27, heat shock 27 kD protein 1; 5-FU, 5-fluorouracil; VCR, vincristine.
Figure 3.
Figure 3.
Tumor sizes in the xenograft model. *P<0.05 vs. the other groups, #P<0.05 vs. control, &P<0.05 vs. control + 5-FU or control + VCR. n=4 in each group. sh, short hairpin; HSP27, heat shock 27 kD protein 1; 5-FU, 5-fluorouracil; VCR, vincristine. Scale bar=100 mm.
Figure 4.
Figure 4.
Effect of shHSP27 and chemotherapy on the phosphorylation and expression of the NOTCH1-Akt-mTOR pathway in vitro. *P<0.05 vs. the other groups, #P<0.05 vs. control + 5-FU group, &P<0.05 vs. control + VCR group. n=4 in each group. sh, short hairpin; HSP27, heat shock 27 kD protein 1; NOTCH1, notch receptor 1; 5-FU, 5-fluorouracil; VCR, vincristine; p, phosphorylated.
Figure 5.
Figure 5.
Effect of shHSP27 and chemotherapy on the phosphorylation and expression of the NOTCH1-Akt-mTOR pathway in vivo. *P<0.05 vs. the others, #P<0.05 vs. control + 5-FU group, &P<0.05 vs. control + VCR group. n=4 in each group. sh, short hairpin; HSP27, heat shock 27 kD protein 1; NOTCH1, notch receptor 1; 5-FU, 5-fluorouracil; VCR, vincristine.

Similar articles

Cited by

References

    1. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271–289. doi: 10.3322/caac.21349. - DOI - PubMed
    1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–193. doi: 10.3322/caac.21395. - DOI - PubMed
    1. Wiseman M. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: A global perspective. Proc Nutr Soc. 2008;67:253–256. doi: 10.1017/S002966510800712X. - DOI - PubMed
    1. Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol. 2004;22:1797–1806. doi: 10.1200/JCO.2004.09.059. - DOI - PubMed
    1. Meyerhardt JA. Adjuvant therapy for stage II and III colon cancer. Clin Adv Hematol Oncol. 2010;8:772–774. - PubMed